BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Montoni A, Robu M, Pouliot E, Shah GM. Resistance to PARP-Inhibitors in Cancer Therapy. Front Pharmacol 2013;4:18. [PMID: 23450678 DOI: 10.3389/fphar.2013.00018] [Cited by in Crossref: 55] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Malka MM, Eberle J, Niedermayer K, Zlotos DP, Wiesmüller L. Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells. Biomolecules 2021;11:981. [PMID: 34356606 DOI: 10.3390/biom11070981] [Reference Citation Analysis]
2 Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny 2016;15:215-9. [PMID: 28250726 DOI: 10.5114/pm.2016.65667] [Cited by in Crossref: 33] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
3 To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) 2014;7:698-707. [PMID: 24817481 DOI: 10.1158/1940-6207.CAPR-14-0047] [Cited by in Crossref: 46] [Cited by in F6Publishing: 23] [Article Influence: 6.6] [Reference Citation Analysis]
4 Gil J, Betancourt LH, Pla I, Sanchez A, Appelqvist R, Miliotis T, Kuras M, Oskolas H, Kim Y, Horvath Z, Eriksson J, Berge E, Burestedt E, Jönsson G, Baldetorp B, Ingvar C, Olsson H, Lundgren L, Horvatovich P, Murillo JR, Sugihara Y, Welinder C, Wieslander E, Lee B, Lindberg H, Pawłowski K, Kwon HJ, Doma V, Timar J, Karpati S, Szasz AM, Németh IB, Nishimura T, Corthals G, Rezeli M, Knudsen B, Malm J, Marko-Varga G. Clinical protein science in translational medicine targeting malignant melanoma. Cell Biol Toxicol 2019;35:293-332. [PMID: 30900145 DOI: 10.1007/s10565-019-09468-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
5 Kim SM, Yang Y, Oh SJ, Hong Y, Seo M, Jang M. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting. J Control Release 2017;266:8-16. [PMID: 28916446 DOI: 10.1016/j.jconrel.2017.09.013] [Cited by in Crossref: 138] [Cited by in F6Publishing: 120] [Article Influence: 34.5] [Reference Citation Analysis]
6 Ha EJ, Lwin CT, Durrant JD. LigGrep: a tool for filtering docked poses to improve virtual-screening hit rates. J Cheminform 2020;12:69. [PMID: 33292486 DOI: 10.1186/s13321-020-00471-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Hussain SA, Sulaiman AA, Balch C, Chauhan H, Alhadidi QM, Tiwari AK. Natural Polyphenols in Cancer Chemoresistance. Nutrition and Cancer 2016;68:879-91. [DOI: 10.1080/01635581.2016.1192201] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 6.4] [Reference Citation Analysis]
8 Zhao Y, Zhang L, Jiang T, Long J, Ma Z, Lu A, Cheng Y, Cao D. The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction. European Journal of Medicinal Chemistry 2020;203:112570. [DOI: 10.1016/j.ejmech.2020.112570] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
9 El Bairi K, Amrani M, Kandhro AH, Afqir S. Prediction of therapy response in ovarian cancer: Where are we now? Critical Reviews in Clinical Laboratory Sciences 2017;54:233-66. [DOI: 10.1080/10408363.2017.1313190] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
10 Ma Y, He L, Huang Q, Zheng S, Zhang Z, Li H, Liu S. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. BMC Med Genet 2018;19:185. [PMID: 30333000 DOI: 10.1186/s12881-018-0703-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Floquet A, Stoeckle E, Croce S, Longy M, Mc Grogan G, Barouk E, Bubien V, Garbay D, Joly E, Guyon F. [Hereditary ovarian carcinomas: clinico-biological features and treatment]. Bull Cancer 2014;101:167-74. [PMID: 24555961 DOI: 10.1684/bdc.2014.1888] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Schreiber V, Illuzzi G, Héberlé E, Dantzer F. De la découverte du poly(ADP-ribose) aux inhibiteurs PARP en thérapie du cancer. Bulletin du Cancer 2015;102:863-73. [DOI: 10.1016/j.bulcan.2015.07.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Jdey W, Kozlak M, Alekseev S, Thierry S, Lascaux P, Girard PM, Bono F, Dutreix M. AsiDNA Treatment Induces Cumulative Antitumor Efficacy with a Low Probability of Acquired Resistance. Neoplasia 2019;21:863-71. [PMID: 31362243 DOI: 10.1016/j.neo.2019.06.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
14 Shah GM, Robu M, Purohit NK, Rajawat J, Tentori L, Graziani G. PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets. Front Oncol 2013;3:279. [PMID: 24294592 DOI: 10.3389/fonc.2013.00279] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
15 Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Chen Y, Plunkett W. Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. Cancer Chemother Pharmacol 2018;81:255-67. [PMID: 29189915 DOI: 10.1007/s00280-017-3483-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, Wang J, Lu Y, Byers LA, Perou CM, Lin SY, Mills GB. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Sci Adv 2017;3:e1600957. [PMID: 28439535 DOI: 10.1126/sciadv.1600957] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
17 Ahmadi Ghezeldasht S, Shamsian SAA, Gholizadeh Navashenaq J, Miri R, Ashrafi F, Mosavat A, Rezaee SA. HTLV-1 oncovirus-host interactions: From entry to the manifestation of associated diseases. Rev Med Virol 2021. [PMID: 33742509 DOI: 10.1002/rmv.2235] [Reference Citation Analysis]
18 Pu H, Horbinski C, Hensley PJ, Matuszak EA, Atkinson T, Kyprianou N. PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis. Carcinogenesis 2014;35:2592-601. [PMID: 25173886 DOI: 10.1093/carcin/bgu183] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
19 Hamilton G, Rath B. A short update on cancer chemoresistance. Wien Med Wochenschr 2014;164:456-60. [PMID: 25249024 DOI: 10.1007/s10354-014-0311-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
20 Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016;22:10254-9. [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
21 Lheureux S, Oza AM. Olaparib for the treatment of ovarian cancer. Expert Opinion on Orphan Drugs 2014;2:497-508. [DOI: 10.1517/21678707.2014.899147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
22 Cashman R, Zilberberg A, Priel A, Philip H, Varvak A, Jacob A, Shoval I, Efroni S. A single nucleotide variant of human PARP1 determines response to PARP inhibitors. NPJ Precis Oncol 2020;4:10. [PMID: 32352035 DOI: 10.1038/s41698-020-0113-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Guney Eskiler G, Cecener G, Egeli U, Tunca B. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer. Pharm Res 2018;35. [DOI: 10.1007/s11095-018-2502-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
24 Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G. Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene 2014;33:3894-907. [PMID: 24037533 DOI: 10.1038/onc.2013.352] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 8.5] [Reference Citation Analysis]
25 Epstein RJ. The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe. Front Oncol 2013;3:304. [PMID: 24377088 DOI: 10.3389/fonc.2013.00304] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
26 Spiegel JO, Van Houten B, Durrant JD. PARP1: Structural insights and pharmacological targets for inhibition. DNA Repair (Amst) 2021;103:103125. [PMID: 33940558 DOI: 10.1016/j.dnarep.2021.103125] [Reference Citation Analysis]
27 Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther 2017;10:5195-208. [PMID: 29138572 DOI: 10.2147/OTT.S139336] [Cited by in Crossref: 71] [Cited by in F6Publishing: 38] [Article Influence: 17.8] [Reference Citation Analysis]
28 Chand S, O'Hayer K, Blanco FF, Winter JM, Brody JR. The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. Int J Biol Sci 2016;12:273-82. [PMID: 26929734 DOI: 10.7150/ijbs.14951] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 11.4] [Reference Citation Analysis]
29 Lim HJ, Ledger W. Targeted therapy in ovarian cancer. Womens Health (Lond) 2016;12:363-78. [PMID: 27215391 DOI: 10.2217/whe.16.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
30 Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA. Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. Cancers (Basel) 2020;12:E972. [PMID: 32295316 DOI: 10.3390/cancers12040972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
31 Bakr A, Köcher S, Volquardsen J, Petersen C, Borgmann K, Dikomey E, Rothkamm K, Mansour WY. Impaired 53BP1/RIF1 DSB mediated end-protection stimulates CtIP-dependent end resection and switches the repair to PARP1-dependent end joining in G1. Oncotarget 2016;7:57679-93. [PMID: 27494840 DOI: 10.18632/oncotarget.11023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
32 Paculová H, Kohoutek J. The emerging roles of CDK12 in tumorigenesis. Cell Div 2017;12:7. [PMID: 29090014 DOI: 10.1186/s13008-017-0033-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
33 Wang Y, Zuo M, Jin H, Lai M, Luo J, Cheng Z. Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer. J Recept Signal Transduct Res 2021;41:304-11. [PMID: 32814472 DOI: 10.1080/10799893.2020.1808676] [Reference Citation Analysis]
34 Paterson R, Phillips KA. Genetic testing in women with breast cancer: implications for treatment. Expert Rev Anticancer Ther 2017;17:991-1002. [PMID: 28853307 DOI: 10.1080/14737140.2017.1374175] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
35 Christenson ES, Antonarakis ES. PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs 2018;23:123-33. [PMID: 29595348 DOI: 10.1080/14728214.2018.1459563] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
36 Ghorai A, Mahaddalkar T, Thorat R, Dutt S. Sustained inhibition of PARP-1 activity delays glioblastoma recurrence by enhancing radiation-induced senescence. Cancer Lett 2020;490:44-53. [PMID: 32645394 DOI: 10.1016/j.canlet.2020.06.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
37 O'Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Front Oncol. 2014;4:42. [PMID: 24616882 DOI: 10.3389/fonc.2014.00042] [Cited by in Crossref: 35] [Cited by in F6Publishing: 51] [Article Influence: 5.0] [Reference Citation Analysis]
38 Guney Eskiler G, Cecener G, Egeli U, Tunca B. Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer. J Cell Physiol 2020;235:6230-45. [PMID: 32017076 DOI: 10.1002/jcp.29552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Steffen JD, Brody JR, Armen RS, Pascal JM. Structural Implications for Selective Targeting of PARPs. Front Oncol 2013;3:301. [PMID: 24392349 DOI: 10.3389/fonc.2013.00301] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 10.4] [Reference Citation Analysis]
40 Min A, Lee KH, Im SA. DNA Damage Repair Inhibitor for Breast Cancer Treatment. Adv Exp Med Biol 2021;1187:159-79. [PMID: 33983578 DOI: 10.1007/978-981-32-9620-6_8] [Reference Citation Analysis]
41 Tentori L, Ricci-Vitiani L, Muzi A, Ciccarone F, Pelacchi F, Calabrese R, Runci D, Pallini R, Caiafa P, Graziani G. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. BMC Cancer 2014;14:151. [PMID: 24593254 DOI: 10.1186/1471-2407-14-151] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
42 Hombach-Klonisch S, Kalantari F, Medapati MR, Natarajan S, Krishnan SN, Kumar-Kanojia A, Thanasupawat T, Begum F, Xu FY, Hatch GM, Los M, Klonisch T. HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells. Mol Oncol 2019;13:153-70. [PMID: 30289618 DOI: 10.1002/1878-0261.12390] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
43 De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. Neoplasia 2014;16:43-72. [PMID: 24563619 DOI: 10.1593/neo.131694] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 9.6] [Reference Citation Analysis]
44 Purohit NK, Shah RG, Adant S, Hoepfner M, Shah GM, Beauregard JM. Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor. Oncotarget 2018;9:24693-706. [PMID: 29872498 DOI: 10.18632/oncotarget.25266] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
45 Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Br J Cancer 2017;116:1021-6. [PMID: 28291774 DOI: 10.1038/bjc.2017.40] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
46 Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18:610-621. [PMID: 28676700 DOI: 10.1038/nrm.2017.53] [Cited by in Crossref: 428] [Cited by in F6Publishing: 360] [Article Influence: 107.0] [Reference Citation Analysis]
47 Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res 2017;19:107. [PMID: 28893315 DOI: 10.1186/s13058-017-0896-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
48 Wang YQ, Wang PY, Wang YT, Yang GF, Zhang A, Miao ZH. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. J Med Chem 2016;59:9575-98. [PMID: 27416328 DOI: 10.1021/acs.jmedchem.6b00055] [Cited by in Crossref: 95] [Cited by in F6Publishing: 76] [Article Influence: 19.0] [Reference Citation Analysis]
49 Kassab MA, Yu LL, Yu X. Targeting dePARylation for cancer therapy. Cell Biosci 2020;10:7. [PMID: 32010441 DOI: 10.1186/s13578-020-0375-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
50 Kassab MA, Yu X. The role of dePARylation in DNA damage repair and cancer suppression. DNA Repair (Amst) 2019;76:20-9. [PMID: 30807923 DOI: 10.1016/j.dnarep.2019.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
51 Vidal RS, Quarti J, Rodrigues MF, Rumjanek FD, Rumjanek VM. Metabolic Reprogramming During Multidrug Resistance in Leukemias. Front Oncol 2018;8:90. [PMID: 29675398 DOI: 10.3389/fonc.2018.00090] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
52 Sistigu A, Manic G, Obrist F, Vitale I. Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol 2016;3:e1053594. [PMID: 27308587 DOI: 10.1080/23723556.2015.1053594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
53 Minchom A, Aversa C, Lopez J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther Adv Med Oncol 2018;10:1758835918786658. [PMID: 30023007 DOI: 10.1177/1758835918786658] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 21.7] [Reference Citation Analysis]
54 Robert M, Patsouris A, Frenel J, Gourmelon C, Augereau P, Campone M. Emerging PARP inhibitors for treating breast cancer. Expert Opinion on Emerging Drugs 2018;23:211-21. [DOI: 10.1080/14728214.2018.1527900] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
55 Srinivasan G, Williamson EA, Kong K, Jaiswal AS, Huang G, Kim HS, Schärer O, Zhao W, Burma S, Sung P, Hromas R. MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers. Proc Natl Acad Sci U S A 2019;116:17438-43. [PMID: 31395736 DOI: 10.1073/pnas.1903150116] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
56 Derbal Y. Perspective on the dynamics of cancer. Theor Biol Med Model 2017;14:18. [PMID: 28969664 DOI: 10.1186/s12976-017-0066-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
57 Lodovichi S, Mercatanti A, Cervelli T, Galli A. Computational analysis of data from a genome-wide screening identifies new PARP1 functional interactors as potential therapeutic targets. Oncotarget 2019;10:2722-37. [PMID: 31105872 DOI: 10.18632/oncotarget.26812] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
58 Falchi F, Giacomini E, Masini T, Boutard N, Di Ianni L, Manerba M, Farabegoli F, Rossini L, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Roberti M, Pellicciari R, Cavalli A. Synthetic Lethality Triggered by Combining Olaparib with BRCA2–Rad51 Disruptors. ACS Chem Biol 2017;12:2491-7. [DOI: 10.1021/acschembio.7b00707] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
59 Zahreddine H, Borden KL. Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 2013;4:28. [PMID: 23504227 DOI: 10.3389/fphar.2013.00028] [Cited by in Crossref: 311] [Cited by in F6Publishing: 266] [Article Influence: 38.9] [Reference Citation Analysis]
60 Robert M, Frenel J, Gourmelon C, Patsouris A, Augereau P, Campone M. Olaparib for the treatment of breast cancer. Expert Opinion on Investigational Drugs 2017;26:751-9. [DOI: 10.1080/13543784.2017.1318847] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
61 Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget 2019;10:3533-46. [PMID: 31191824 DOI: 10.18632/oncotarget.26947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
62 Heitmann J, Geeleher P, Zuo Z, Weichselbaum RR, Vokes EE, Fetscher S, Seiwert TY. Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. Oral Oncol 2014;50:825-31. [PMID: 25017803 DOI: 10.1016/j.oraloncology.2014.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
63 Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Update on PARP Inhibitors in Breast Cancer. Curr Treat Options Oncol 2018;19:21. [PMID: 29644491 DOI: 10.1007/s11864-018-0540-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 14.7] [Reference Citation Analysis]
64 Rosen EM. BRCA1 in the DNA damage response and at telomeres. Front Genet 2013;4:85. [PMID: 23802008 DOI: 10.3389/fgene.2013.00085] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]